{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007900","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.168717+00:00","generated_at":"2026-06-18T00:39:14.750872+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share","bullets":["Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.","Net loss $14.2M ($0.45 diluted EPS) vs net income $36.7M ($1.23) prior year.","Operating loss $27.0M, driven by lower revenue, goodwill impairment, R&D for Co-Dx PCR Home.","Adjusted net income (excl. goodwill) $1.2M, or $0.04 per diluted share.","Initiated clinical evaluations for Co-Dx PCR Home platform; cash $81.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007900","json":"https://secwatch.observer/filing/0001493152-23-007900.json","markdown":"https://secwatch.observer/filing/0001493152-23-007900.md","text":"https://secwatch.observer/filing/0001493152-23-007900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/0001493152-23-007900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:39:14.750872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7a4f7e2784f39e86df178104a9884f5f6c082ae","claim":"Co-Diagnostics, Inc. reported the full year ended December 31, 2022 results: revenue $34.2 million, net income $14.2 million, EPS $0.45 per fully diluted share.","evidence_excerpt":"the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. Full Year 2022 Financial Results: ● Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $28.7 million, representing 84.0% of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/0001493152-23-007900-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$34.2 million"},{"label":"Net income","value":"$14.2 million"},{"label":"EPS","value":"$0.45 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}